Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 10 (5), 377-93

Priorities in Parkinson's Disease Research

Affiliations
Review

Priorities in Parkinson's Disease Research

Wassilios G Meissner et al. Nat Rev Drug Discov.

Abstract

The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting tremors. Although these symptoms can be improved using currently available dopamine replacement strategies, there is still a need to improve current strategies of treating these symptoms, together with a need to alleviate non-motor symptoms of the disease. Moreover, treatments that provide neuroprotection and/or disease-modifying effects remain an urgent unmet clinical need. This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address these treatment goals. Progress will rely on understanding genetic mutations or susceptibility factors that lead to Parkinson's disease, better translation between preclinical animal models and clinical research, and improving the design of future clinical trials.

Similar articles

See all similar articles

Cited by 125 articles

See all "Cited by" articles

References

    1. Clin Neuropharmacol. 2008 May-Jun;31(3):141-50 - PubMed
    1. Mov Disord. 2008 Apr 15;23(5):690-9 - PubMed
    1. Ann Neurol. 2003 Jul;54(1):93-101 - PubMed
    1. CNS Neurosci Ther. 2008 Winter;14(4):352-65 - PubMed
    1. Eur J Neurol. 2005 Dec;12(12):956-63 - PubMed
Feedback